
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc is positioned for significant growth due to a robust pipeline of treatments addressing serious and rare diseases, with a particularly promising outlook for its lead product, ARIKAYCE, projected to generate global revenues of $405M to $425M by 2025. The anticipated launch of Brensocatib in 2025 is expected to be highly successful, potentially reaching peak sales of $8.2B, driven by strong demand from both patients and physicians in a market with limited alternative treatments. Additionally, Insmed's recent expansion of its commercial infrastructure, including an increase in sales representatives and strategic market access initiatives, further enhances its operational capabilities to capitalize on upcoming launches and pipeline potential.
Bears say
Insmed Inc faces significant challenges that contribute to a negative outlook for its stock, primarily due to risks associated with its clinical pipeline, including potential safety issues, regulatory hurdles, and efficacy concerns that could impede the progress of its drug candidates. The company reported substantial net losses of $235.5 million for the fourth quarter of FY24 and $913.8 million for the fiscal year, raising concerns about its financial viability if its products fail to generate sufficient revenue. Given the ongoing financial pressures coupled with high research and development expenditures, there is a risk that Insmed may struggle to finance its operations, especially if its commercial ventures do not succeed.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares